Dr. Kasim A. Mookhtiar is the co-founder, Chief Executive of Advinus Therapeutics Ltd, India’s first innovative pharmaceutical research and development company, which is funded and supported by the Tata group of companies. Prior to co-founding Advinus, he was Vice President, New Drug Discovery Research, at Ranbaxy Laboratories Limited, where he led a team of over 200 scientists from multiple disciplines.
After completing a 5-year integrated MS in Chemistry at the Indian Institute of Technology, Bombay, where he worked in Synthetic Organic Chemistry, Kasim pursued a PhD with Professor H. E. Van Wart at the Institute of Molecular Biophysics, Florida State University, Tallahassee, Florida, USA. His graduate work encompassed biochemistry, protein chemistry, enzyme kinetics and inhibition. Kasim followed up his graduate work with a postdoctoral stint at Yale University School of Medicine, where he learned molecular biology and structural biology (2D NMR).
He joined the Metabolic Diseases Drug Discovery group at the Bristol-Myers Squibb Pharmaceutical Research Institute in Princeton, NJ, USA, where he worked from1992 to 2003. Early in his career he pioneered of the Diabetes and Obesity programs at BMS and was then entrusted with the task of forming the Department of Aging Research in Drug Discovery, a very novel and cutting edge area for both basic and applied research. He was responsible for the strategic planning of this area and was also involved in numerous strategic efforts in the wider BMS activities.